- Home
- EXEL vs MDGL Comparison
EXEL vs MDGL Comparison
Compare EXEL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | MDGL |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.5B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EXEL | MDGL |
|---|---|---|
| Price | $50.11 | $525.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | $46.50 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.7M | 257.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | 41.32 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $452,477,000.00 | $180,133,000.00 |
| Revenue This Year | $13.61 | $58.39 |
| Revenue Next Year | $13.13 | $48.55 |
| P/E Ratio | $64.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.76 | $265.00 |
| 52 Week High | $51.63 | $615.00 |
Technical Indicators
Market Signals| Indicator | EXEL | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 53.44 |
| Support Level | $40.17 | $502.45 |
| Resistance Level | N/A | $556.79 |
| Average True Range (ATR) | 1.60 | 21.98 |
| MACD | 0.51 | -0.50 |
| Stochastic Oscillator | 82.66 | 51.98 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.